|Year : 2010 | Volume
| Issue : 1 | Page : 30-34
Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India
Ketan K Patel1, Atul K Patel1, Rajiv R Ranjan1, Apurva R Patel1, Jagdish K Patel2
1 Infectious Diseases Consultant, Infectious Diseases Clinic, Navarangpura, Ahmedabad - 380 009, India
2 Adit Molecular Diagnostic Center, "VEDANTA" Institute of Medical Sciences, Navarangpura, Ahmedabad - 380 009, India
|Date of Web Publication||3-Sep-2010|
Atul K Patel
3rd Floor, Infectious Diseases Clinic, "Vedanta" Institute of Medical Sciences, Navarngpura. Ahmedabad - 380 009
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: Tenofovir (TDF) is preferred nucleoside reverse transcriptase inhibitors (NRTI) for the treatment of human immunodeficiency virus infection because of its potency and safety. Renal toxicity with TDF use is low and comparable with other NRTI in clinical trials, but there are many case studies and small case series of renal dysfunction with TDF. Materials and Methods: This is an observational longitudinal cohort of patients started on a TDF-based regimen from January 2007 to April 2010. Patients were evaluated at baseline and with every follow-up visit for serum creatinine and calculated creatinine clearance (Cockroft-Gault formula). In addition to this, the patients were also subjected to test for serum potassium, phosphorous and urine examinations as and when indicated. Renal dysfunction was defined as rise in serum creatinine to more than the upper level of normal (>1.2 mg%). Results: Of 1,271 patients started on a TDF-containing antiretroviral treatment (ART) 83 (6.53%) developed renal dysfunction, of which 79 had impaired serum creatinine and five had Fanconi's syndrome. Renal dysfunction was more common with boosted a protease inhibitor (PI) (9.44%)-based regimen as compared to a non- nucleoside reverse transcriptase inhibitors (NNRTI) (5.01%)-based regimen (P = 0.003). The mean decline in creatinine clearance from baseline was 22.27 ml/min. The median time to develop renal dysfunction was 154 (15-935) days. Serum creatinine returned to normal in all the patients after stopping TDF. Five patients presented with features suggestive of Fanconi's syndrome without alteration in serum creatinine. Conclusion: TDF-based treatment is associated with mild but reversible renal dysfunction. Patients receiving PI/r are at a higher risk of renal dysfunction compared to those receiving NNRTI-based ART. Clinicians should be adviced to have intensive renal monitoring, including creatinine clearance, urine examination, K+ and phosphate levels at baseline and during treatment with TDF.
Keywords: Antiretroviral therapy, nephrotoxicity, renal dysfunction, tenofovir
|How to cite this article:|
Patel KK, Patel AK, Ranjan RR, Patel AR, Patel JK. Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India. Indian J Sex Transm Dis 2010;31:30-4
|How to cite this URL:|
Patel KK, Patel AK, Ranjan RR, Patel AR, Patel JK. Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India. Indian J Sex Transm Dis [serial online] 2010 [cited 2018 Jan 23];31:30-4. Available from: http://www.ijstd.org/text.asp?2010/31/1/30/68998
| Introduction|| |
Tenofovir disoproxil fumarate (TDF) is an oral prodrug of tenofovir, an acyclic nucleoside phosphonate. TDF is the first nucleotide analogue reverse transcriptase inhibitor to be approved for the treatment of human immunodeficiency virus (HIV) infection. ,,,
TDF is extensively excreted by the renal route by means of glomerular filtration, with 20-30% being actively transported into the renal proximal tubule cells by organic anion transporter 1 (OAT-1). Boosted protease inhibitor (PI/r)-based therapies can increase the plasma exposure of TDF by 20-30%. 
TDF is generally considered safe; however, renal toxicity has been reported with its use. ,,,, Even though TDF most often has been reported to cause proximal renal tubulopathy, e.g., Fanconi syndrome, other related nephrotoxicities, including diabetes insipidus, calcium and phosphorus dysregulation with bone disease,  and reduction in glomerular function have also been reported. , Although the incidence of nephrotoxicity appears to be low (ranging from 0.3 to 2%), many caregivers will see this complication develop due to the agent's widespread use. Risk factors include low body weight, impaired renal function at baseline and concomitant receipt of nephrotoxic drugs. ,, Although in most cases tubular dysfunction is reversible after withdrawal of TDF, , persistent renal damage with renal dysfunction has been reported. , Here, we describe renal dysfunction in patients started on a TDF-containing regimen.
| Materials and Methods|| |
In this observational longitudinal cohort, patients started on a TDF-based regimen were evaluated at baseline and with every follow-up visit for serum creatinine and calculated creatinine clearance. In addition to this, the patients were also subjected to test for serum potassium, phosphorous and urine examinations as and when indicated. Baseline demographic data were collected. Renal dysfunction was defined as  rise in serum creatinine to more than the upper level of normal (>1.2 mg%).  Laboratory evidence of Fanconi syndrome, e.g. hypokalemia, hypophosphatemia and normoglycemic glycosuria. Creatinine clearance was calculated using the Cockroft-Gault formula. Data were analyzed using descriptive statistics and chi-square test.
| Results|| |
From January 2007 to April 2010, 1,271 patients were started on a TDF-containing regimen. Details are given in [Figure 1].
In the NNRTI group, 784 and 53 patients were on efavirenz (EFV) and nevirapine (NVP)-based regimens, respectively, while in the boosted PI group, 188, 132, 103 and 11 patients were on atazanavir/r (ATV/r), indinavir/r (IDV/r), lopinavir/r (LPV/r) and saquinavir/r (SAQ/r)-based regimens, respectively. The baseline characteristics of patients are as given in [Table 1].
Of all the patients (n = 1,271), a total of 83 (6.53%) developed TDF renal dysfunction, of which 42 (5.01%) patients were started on an NNRTI-based regimen, while 41 (9.44%) were on a PI/r-based regimen. Of the 83 patients, 78 (6.14%) patients had developed rise in creatinine level to more than the upper limit of normal and five patients (0.39%) had developed proximal tubular dysfunction. Median time to developing renal dysfunction was 154 (15-935) days.
Mean decline in creatinine clearance from baseline was 22.27 mL/min at the time of renal dysfunction. Urine examination of these patients with elevated serum creatinine showed either normal examination or trace to 1+ albumin without active sediments. All patients with impaired serum creatinine recovered after discontinuation of TDF. Three patients with elevated serum creatinine who were allowed to continue TDF for further 2 weeks showed a further worsening of the serum creatinine. This suggests a drug related renal dysfunction most likely a tubulo-interstitial injury. Patients with rise in serum creatinine were largely asymptomatic while five patients presented with weakness, bone pains and backache; of these, two had severe pain and had difficulty in walking. All five patients had refractory hypokalemia and hypophosphatemia with normal serum creatinine levels, and two of them had normoglycemic glycosuria to complete features of Fanconi syndrome. Two patients who underwent Dual energy x-ray absorptiometry (DEXA) scans showed severe osteoporosis. Plain X-ray examination of both knees in patient with bone pains showed osteoporosis [Figure 2].
Patients on the PI/r-based regimen had higher chances of developing TDF toxicity compared to patients on the NNRTI-based regimen (P = 0.003). Ritonavir dosage/day (200 mg vs. 100 mg) was not found to be associated with an increased risk of TDF renal dysfunction (P = 0.1582). Similarly, no statistically significant difference was observed for TDF-associated renal dysfunction between the ATV/r (100 mg of ritonavir/day) and NNRTI group (P = 0.4212). The observed renal dysfunction with different regimens used was as follows: EFV = 39 (4.97%), NVP = 2 (3.77%), SAQ = 2 (18.18%), ATV = 13 (6.91%), IDV = 13 (9.85%), LPV = 9 (8.74%).
The associated comorbidities and possible risk factors for renal dysfunction in our cohort were hypertension/CAD (12.04%), chronic liver diseases (HCV, 9.63%), prolonged survival with HIV (>10 years, 8.43%), diabetes (8.43%), renal calculi (7.23%) and single kidney (1.20%).
No patients received concomitant nephrotoxic drugs.
| Discussion|| |
TDF is currently recommended as a first-line agent in combination with other antiretrovirals for HIV management because of its favorable pharmacokinetic profile, good antiviral potency, high tolerability and low incidence of mitochondrial toxicities. Because of the availability of generic medicine and efficacy-safety profile, TDF usage has increased in developing countries. TDF has been considered safe and associated with fewer side-effects, including renal dysfunction, in clinical trials. ,,, However, there have been many case reports and cohort studies describing TDF-associated nephrotoxicity. ,,,,,,,,,
Clinically, the spectrum of TDF-associated nephrotoxicity spans all levels of severity, from mild renal tubular dysfunction with subclinical decline in renal function to classical Fanconi syndrome.
The majority of the patients (6.14%) in our cohort had elevated creatinine with normal urine examination, except trace to 1+ albuminuria, which suggests tubulointerstitial injury due to TDF, while 0.39% had clinical and biochemical features favoring proximal tubular dysfunction. Patients in our cohort who were allowed to continue TDF showed progressive renal injury. which favors drug-related injury.
Known risk factors for the development of TDF-induced nephrotoxicity include underlying renal dysfunction, low CD4 count and low body weight, ,,, concomitant use of boosted PI and other nephrotoxic agents. Of the 164 patients with TDF-induced Fanconi syndrome reported to the FDA, the majority (83%) were treated with protease inhibitors, specifically, 74% had received a ritonavir-boosted regimen. Although discontinuation of TDF results in renal recovery in the majority of the cases, some patients experience chronic kidney disease. Similar to our observation (p=0.003, other studies have found that patients receiving ritonavir-boosted PI have greater TDF-associated renal function decline compared to the NNRTI-based therapy, , In all these patients, laboratory abnormalities rapidly improved after stopping the TDF. The median body weight in our cohort was 60 (40-112) kg, suggesting that lesserweight may not be an important factor predisposing to renal dysfunction. Other risk factors for renal dysfunction in our cohort were hypertension/CAD (12.04%), chronic liver diseases (HCV-related, 9.63%), prolonged survival with HIV (>10 years, 8.43%), diabetes (8.43%), renal calculi (7.23%) and single kidney (1.20%). Rachel et al., in his study, showed that antiretroviral-naive patients have a statistically significant raised creatinine levels with an increasing probability of developing raised creatinine level during follow-up (P < 0.001), which contrast with our finding. This study also brings out other factorsth , such as non-compliance, hepatitis C virus coinfection and intravenous drug use, as risk factors for TDF toxicity. 
The mechanisms underlying these renal toxicities are not fully understood. TDF and its more nephrotoxic sister drugs, adefovir and cidofovir, undergo active tubular secretion. Because intracellular drug accumulation is a function of uptake and secretion, enhanced uptake via the OAT-1 on the basolateral membrane or impaired efflux via one or more of the apical transporters can, in theory, result in drug accumulation and potential toxicity. , Mitochondrial DNA depletion by the accumulated high intracellular drug levels has been proposed as a mechanism of the renal toxicity associated with NRTI use. , It is important to note that TDF is a weak inhibitor of DNA polymerase gamma than are the other NRTIs. Administration of ritonavir alone or with lopinavir has been shown to increase the maximum serum concentrations of tenofovir by >30%, and it is likely that ritonavir increased the proximal tubular concentrations of tenofovir by decreasing its urinary secretion, thereby leading to TDF toxicity.
In our cohort, higher ritonavir dosage (200 vs. 100 mg/day) as a PI booster was not associated with an increased incidence of renal dysfunction with TDF.
The article by Irizarry-Alvarado and coworkers highlights not only the synergistic nephrotoxic potential of TDF and didanosine,  fortunately a rarely used NRTI combination in current practice, but also points out the need to monitor renal function, phosphate levels, urinalysis for glycosuria and urinary protein excretion on a regular basis in patients receiving TDF.
As suggested before,  we also recommend especially for clinicians practicing in resource-limited settings to be vigilant and keep looking for TDF-related renal toxicity, which although reversible can lead to significant morbidity.
Through a very simple definition used to define renal dysfunction in this manuscript, it gives important information to sensitize the practicing doctors about TDF-associated renal toxicity. As described, majority of the patients had milder and reversible renal dysfunction following TDF use. This information should be useful for a clinician to diagnose TDF related renal toxicity early and manage its severe forms with associated morbidity.
| Conclusions|| |
TDF-based treatment is associated with mild but reversible renal dysfunction. Patients receiving PI/r are at a higher risk of renal dysfunction compared to NNRTI-based ART. Clinicians are adviced to monitor renal function aggressively by calculating creatinine clearance and doing a urine examination, K + and phosphate levels at baseline and during follow up with TDF use.
| References|| |
|1.||Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-60. |
|2.||Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004;292:191-201. |
|3.||Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years. AIDS 2007;21:1273-81. |
|4.||Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005;20:743-6. |
|5.||Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis 2006;42:283-90. |
|6.||Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004;18:960-3. |
|7.||Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004;117:282-4. |
|8.||Rollot F, Nazal EM, Chauvelot-Moachon L, Kιlaοdi C, Daniel N, Saba M, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: The role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003;37:e174-6. |
|9.||Peyriθre H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, et al. Renal tubular dysfunction associated with tenofovir therapy: Report of 7 cases. J Acquir Immune Defic Syndr 2004;35:269-73. |
|10.||Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009;10:482-7. |
|11.||Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003;17:935-7. |
|12.||Szczech LA. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top HIV Med 2008;16:122-6. |
|13.||Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-3. |
|14.||Antoniou T, Raboud J, Chirhin S, Yoong D, Govan V, Gough K, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: A retrospective cohort study. HIV Med 2005;6:284-90. |
|15.||Gupta SK. Editorial comment: Tenofovir-related nephrotoxicity--who's at risk? AIDS Read 2007;17:102-3. |
|16.||Atta MG, Fine DM. Editorial comment: Tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice. AIDS Read 2009;19:118-9. |
|17.||Coca S, Perazella MA. Rapid communication: Acute renal failure associated with tenofovir: Evidence of drug-induced nephrotoxicity. Am J Med Sci 2002;324:342-4. |
|18.||Gupta SK. Tenofovir-associated Fanconi syndrome: Review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008;22:99-103. |
|19.||Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez JC. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: A report of 3 cases. AIDS Read 2009;19:114-21. |
|20.||James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovir-related nephrotoxicity: Case report and review of the literature. Pharmacotherapy 2004;24:415-8. |
|21.||Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: A cohort and case-control study. J Acquir Immune Defic Syndr 2004;37:1489-95. |
|22.||Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197:102-8. |
|23.||Buchacz K, Young B, Baker RK, Moorman A, Chmiel JS, Wood KC, et al. Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort. J Acquir Immune Defic Syndr 2006;43:626-8. |
|24.||Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:1559-85. |
|25.||Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, Russ R, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 2009;89:513-9. |
|26.||Fine DM. Editorial comment: Tenofovir nephrotoxicity--vigilance required. AIDS Read 2005;15:362-3. |
[Figure 1], [Figure 2]
|This article has been cited by|
||Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: A comparative cohort analysis between Western India and United Kingdom
| ||Sanjay N Pujari,Colette Smith,Abhimanyu Makane,Mike Youle,Margaret Johnson,Vivek Bele,Kedar Joshi,Digamber Dabhade,Sanjay Bhagani |
| ||BMC Infectious Diseases. 2014; 14(1): 173 |
|[Pubmed] | [DOI]|
||Tenofovir Renal Toxicity: Evaluation of Cohorts and Clinical Studies—Part One
| ||Adikwu Elias,Ogbuehi Ijeoma,Nkereuwem Jonathan Edikpo,Deo Oputiri,Oru-Bo Precious Geoffrey |
| ||Pharmacology & Pharmacy. 2013; 04(09): 651 |
|[Pubmed] | [DOI]|
||Tenofovir induced Fanconi syndrome: A possible pharmacokinetic interaction
| ||Kapadia, J. and Shah, S. and Desai, C. and Desai, M. and Patel, S. and Shah, A. and Dikshit, R. |
| ||Indian Journal of Pharmacology. 2013; 45(2): 191-192 |